Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-74 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7151 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B40-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-02 |
filingDate |
2013-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b387614a95f6ad1c02b0320a90da3c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc24c276c8e1d7ca38b2976fd51c118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5538b2cfa1117da228434bb1264fa15 |
publicationDate |
2014-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014234334-A1 |
titleOfInvention |
Peptides and related molecules that bind to tall-1 |
abstract |
The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz 2 Lz 4 wherein z 2 is an amino acid residue and z 4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae n (SEQ. ID. NO: 100) a 1 a 2 a 3 CDa 6 La 8 a 9 a 10 Ca 12 a 13 a 14 , (SEQ. ID. NO: 104) b 1 b 2 b 3 Cb 5 b 6 Db 8 Lb 10 b 11 b 12 b 13 b 14 Cb 16 b 17 b 18 (SEQ. ID. NO: 105) c 1 c 2 c 3 Cc 5 Dc 7 Lc 9 c 10 c 11 c 12 c 13 c 14 Cc 16 c 17 c 18 (SEQ. ID. NO: 106) d 1 d 2 d 3 Cd 5 d 6 d 7 WDd 10 Ld 13 d 14 d 15 Ld 16 d 17 d 18 (SEQ. ID. NO: 107) e 1 e 2 e 3 Ce 5 e 6 e 7 De 9 Le 11 Ke 13 Ce 15 e 16 e 17 e 18 (SEQ. ID NO: 109) f 1 f 2 f 3 Kf 5 Df 7 Lf 9 f 10 Qf 12 f 13 f 14 nwherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formulan n (X 1 ) a —V 1 —(X 2 ) b n n wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11242397-B2 |
priorityDate |
2001-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |